Michigan football offensive coordinator Calvin Magee kept quiet Wednesday afternoon when asked if Wolverines quarterback Tate Forcier had earned back his wings yet. "I won't tell you that," Magee said, before adding, "I have mine." Multiple members of the Michigan football team had wings stripped from their helmets this summer, ...
Eating healthy on the go is a challenge requiring good planning and creative ideas and snacks are an important part of daily healthy meal plans. Keep these healthy snacks in mind when your at the grocery store then incorporate them into your healthy eating plan as snacks that will keep ...
Since our launch 10 months ago, AnnArbor.com has worked to expand our coverage area and bring you stories not just from Ann Arbor, but from surrounding communities as well. One of our top priorities is to provide you with news and information about the vibrant community of Saline. Today, we ...
Marlin Jackson has taken some ribbing from his NFL teammates over Michigan’s 8-16 record the last two years. It’s been good-natured and fun-loving, but hard to swallow nonetheless. “I don’t know where we’re headed,” Jackson said. “I don’t want to say, but I just don’t know where we’re headed. What ...
Ann Arbor-based biotechnology firm NanoBio Corp. has received a U.S. patent that solidifies intellectual property rights considered key to its top products, the company announced today. NanoBio, a University of Michigan spinoff firm, was awarded a patent pertaining to its platform vaccine technology and anti-infective product candidate.
University of Michigan spinoff biotech firm Lycera Corp. has hired a CEO and is shifting its official headquarters to Massachusetts, where the new executive lives. Lycera hired Boston area pharmaceutical industry veteran William J. Sibold as its CEO but plans to maintain its research operation at the Michigan Life Science ...
Timothy Mayleben is endowed with the Esperion Therapeutics mystique. Whether that helps him rescue Ann Arbor-based biotechnology firm Aastrom Biosciences is to be determined. Mayleben, a longtime Aastrom board member, became CEO last week after ex-CEO George Dunbar asked him to take over. Dunbar will remain chairman in a transition ...
Ann Arbor-based NanoBio Corp. announced today that it's signed an agreement with United Kingdom-based pharmaceutical giant GlaxoSmithKline to license its cold sore treatment still in clinical development. The deal provides $14.5 million upfront to NanoBio in addition to royalties and payments of up to $40 million if the treatment hits specific ...
The deal for Ann Arbor medical devices firm HandyLab, a promising technology company often held up as a bright spot in the local economy, has been finalized by New Jersey-based medical devices manufacturer Becton, Dickinson and Company. BD paid $275 million for HandyLab, according to a release issued this morning. ...
Ann Arbor-based Aastrom Biosciences is launching another Phase 2 clinical trial to study the effectiveness of its cell treatment for a disease that causes chronic heart failure. The clinical trial will examine whether Aastrom’s cardiac repair cell technology, delivered through a catheter, can treat dilated cardiomyopathy (DCM). The trial will ...
The global medical devices company that’s acquiring Ann Arbor-based HandyLab expects to leverage the opportunity to expand into new markets, executives said today. New Jersey-based Becton, Dickinson and Co., which announced Oct. 23 that it would buy University of Michigan spinoff HandyLab, is expected to finish the acquisition this month.
For most early-stage biotech companies, revenue is but a far-off dream. They rely mostly on investors’ cash or government funding until they’re advanced enough to market a drug or sign licensing deals with major pharmaceutical companies. But the global economic crisis, which has caused investors to scale back on funding ...
The sluggish production process for the swine flu vaccine illustrates the global potential of an Ann Arbor biotech company’s technology. Antiquated vaccine production technology, which is making it difficult for manufacturers to quickly produce H1N1 flu vaccines, is creating demand for a revolutionary alternative. That's where University of Michigan spinoff ...
Not too many people get the chance to start the same company twice. But Esperion Therapeutics founder Roger Newton is reaping the benefits of learning from his company’s first mistakes and successes. Newton, the Ann Arbor scientist who famously co-discovered Lipitor, the world’s top-selling drug, is cognizant that the second ...
Angela J. Cesere | AnnArbor.com AnnArbor.com's partner news site MLive.com is on a quest to find the best barbecue in ......
Get the Ann Arbor RSS Feed
AnnArbor.com